de la Fuente Alex, Mena-Barragán Teresa, Farrar-Tobar Ronald A, Verdaguer Xavier, García Fernández José M, Ortiz Mellet Carmen, Riera Antoni
Institute for Research in Biomedicine (IRB Barcelona), Baldiri Reixac 10, E-08028 Barcelona, Spain.
Org Biomol Chem. 2015 Jun 21;13(23):6500-10. doi: 10.1039/c5ob00507h. Epub 2015 May 15.
2-Acetamido-1,2-dideoxyiminosugars are selective and potent inhibitors of hexosaminidases and therefore show high therapeutic potential for the treatment of various diseases, including several lysosomal storage disorders. A stereoselective synthesis of 2-acetamido-1,2-dideoxynojirimycin (DNJNAc), the iminosugar analog of N-acetylglucosamine, with a high overall yield is here described. This novel procedure further allowed accessing ureido-DNJNAc conjugates through derivatization of the endocyclic amine on a key pivotal intermediate. Remarkably, some of the ureido-DNJNAc representatives behaved as potent and selective inhibitors of β-hexosaminidases, including the human enzyme, being the first examples of neutral sp(2)-iminosugar-type inhibitors reported for these enzymes. Moreover, the amphiphilic character of the new ureido-DNJNAc is expected to confer better drug-like properties.
2-乙酰氨基-1,2-二脱氧亚氨基糖是己糖胺酶的选择性强效抑制剂,因此在治疗包括多种溶酶体贮积症在内的各种疾病方面显示出很高的治疗潜力。本文描述了一种立体选择性合成2-乙酰氨基-1,2-二脱氧野尻霉素(DNJNAc)的方法,其为N-乙酰葡糖胺的亚氨基糖类似物,总产率较高。这一新颖的方法还能通过关键中间体上的环内胺衍生化来制备脲基-DNJNAc缀合物。值得注意的是,一些脲基-DNJNAc衍生物表现为β-己糖胺酶(包括人源酶)的强效选择性抑制剂,是报道的这些酶的中性sp(2)-亚氨基糖型抑制剂的首例。此外,新型脲基-DNJNAc的两亲性有望赋予其更好的类药性质。